Allergy Therapeutics plc (LON:AGY - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as GBX 7 ($0.09) and last traded at GBX 6.53 ($0.08), with a volume of 2477185 shares. The stock had previously closed at GBX 6.80 ($0.09).
Allergy Therapeutics Stock Performance
The business has a fifty day simple moving average of GBX 5.61 and a two-hundred day simple moving average of GBX 5.09. The company has a market cap of £311.24 million, a PE ratio of -108.75, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Recommended Stories
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
